Short answer
Vertex Pharmaceuticals (VRTX) filed its Q1 2025 10-Q quarterly report on May 6, 2025 for the quarter ended Mar 31, 2025. Quarterly revenue was $2.8B (up 3.0% year over year) with net income of $646M.
Q1 2025 key financials · XBRL
- Revenue
- $2.8B
- +3.0% YoY
- Net income
- $646M
- −41.2% YoY
- Operating margin
- 22.7%
- EPS (diluted)
- $2.49
- −40.9% YoY
Source: XBRL data from the Vertex Pharmaceuticals (VRTX) Q1 2025 10-Q on SEC EDGAR. USD.
Vertex Pharmaceuticals Q1 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly added risk factors disclosed, risk section focuses on forward-looking statements and general uncertainties
- Regulatory risk emphasized on timing and uncertainty of clinical trial data, regulatory filings, and approvals for pipeline therapies
- Operational risk related to building and maintaining global supply chains and manufacturing capabilities for cell and gene therapies
- Market risk tied to ability to grow cystic fibrosis business by increasing eligible patient base and providing improved treatments
- Financial risk highlighted in foreign currency exchange fluctuations and cash generated from operations impacting liquidity and capital raising
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vertex Pharmaceuticals quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.